6p21 rearrangements in uterine leiomyomas targeting HMGA1

Cancer Genetics and Cytogenetics Pub Date : 2010-12-01 DOI:10.1016/j.cancergencyto.2010.08.005

Maliheh Hashemi Nezhad , Norbert Drieschner , Sabrina Helms , Anke Meyer , Mahboobeh Tadayyon , Markus Klemke , Gazanfer Belge , Sabine Bartnitzke , Käte Burchardt , Christiane Frantzen , Ernst Heinrich Schmidt , Jörn Bullerdiek

{"title":"6p21 rearrangements in uterine leiomyomas targeting HMGA1","authors":"Maliheh Hashemi Nezhad , Norbert Drieschner , Sabrina Helms , Anke Meyer , Mahboobeh Tadayyon , Markus Klemke , Gazanfer Belge , Sabine Bartnitzke , Käte Burchardt , Christiane Frantzen , Ernst Heinrich Schmidt , Jörn Bullerdiek","doi":"10.1016/j.cancergencyto.2010.08.005","DOIUrl":null,"url":null,"abstract":"<div>To quantify the expression of HMGA1 mRNA in uterine leiomyomas, the expression of HMGA1 was analyzed in a series including tumors with aberrations of chromosome 6 (n = 7) and cytogenetically normal tumors (n = 8) as a control group by quantitative reverse transcriptase–polymerase chain reaction. The average expression level in the 6p21 group was found to be 5.6 times higher than that in the control group, and with one exception, all cases with 6p21 alteration revealed a high expression of HMGA1 mRNA than cytogenetically normal tumors. Nevertheless, compared to fibroids with a normal karyotype, the upregulation of the HMGA1 mRNA in these cases was much less strong than that of HMGA2 mRNA in case of 12q14∼15 aberrations identified in previous studies.</div>","PeriodicalId":55596,"journal":{"name":"Cancer Genetics and Cytogenetics","volume":"203 2","pages":"Pages 247-252"},"PeriodicalIF":0.0000,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cancergencyto.2010.08.005","citationCount":"35","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genetics and Cytogenetics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165460810004462","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 35

Abstract

To quantify the expression of HMGA1 mRNA in uterine leiomyomas, the expression of HMGA1 was analyzed in a series including tumors with aberrations of chromosome 6 (n = 7) and cytogenetically normal tumors (n = 8) as a control group by quantitative reverse transcriptase–polymerase chain reaction. The average expression level in the 6p21 group was found to be 5.6 times higher than that in the control group, and with one exception, all cases with 6p21 alteration revealed a high expression of HMGA1 mRNA than cytogenetically normal tumors. Nevertheless, compared to fibroids with a normal karyotype, the upregulation of the HMGA1 mRNA in these cases was much less strong than that of HMGA2 mRNA in case of 12q14∼15 aberrations identified in previous studies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

6p21重排在靶向HMGA1的子宫平滑肌瘤中的作用

为了量化HMGA1 mRNA在子宫平滑肌瘤中的表达，我们采用定量逆转录-聚合酶链反应分析了HMGA1在6号染色体畸变肿瘤(n = 7)和细胞遗传学正常肿瘤(n = 8)作为对照组中的表达情况。6p21组的平均表达水平是对照组的5.6倍，除了一个例外，所有6p21改变的病例HMGA1 mRNA的表达都比细胞遗传学正常的肿瘤高。然而，与正常核型的肌瘤相比，这些病例中HMGA1 mRNA的上调远不如先前研究中发现的12q14 ~ 15畸变的HMGA2 mRNA的上调强。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Genetics and Cytogenetics 医学-遗传学

自引率

0.00%

发文量

审稿时长

>12 weeks